MBX Biosciences, Inc.
Metsera, Inc. (Nasdaq: MBX) is a clinical-stage biopharmaceutical company discovering and developing precision peptide therapies for endocrine and metabolic disorders. Its proprietary Precision Endocrine Peptide platform combines peptide design, programmable prodrug technologies and fatty acylation to develop… From the company’s description.
In fiscal 2025, MBX Biosciences, Inc. reported a net loss of $86.97M. Operations used $79.95M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What MBX Biosciences, Inc. does
In the company’s own words
Metsera, Inc. (Nasdaq: MBX) is a clinical-stage biopharmaceutical company discovering and developing precision peptide therapies for endocrine and metabolic disorders. Its proprietary Precision Endocrine Peptide platform combines peptide design, programmable prodrug technologies and fatty acylation to develop candidates with extended action and less frequent dosing. The pipeline includes canvuparatide, a potential once-weekly parathyroid hormone replacement therapy for chronic hypoparathyroidism; MBX 4291, a GLP-1/GIP co-agonist prodrug being evaluated for obesity; and imapextide, a GLP-1 receptor antagonist in development for post-bariatric hypoglycemia. The company also has multiple discovery programs in lead optimization. Its candidates are in clinical development, and the company has not generated revenue from product sales. The company was founded around peptide research and chemical technologies originating at Indiana University. Its website is https://www.metsera.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- CARMEL, IN
- Fiscal year end
- December
- CIK
- 1776111
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns MBX Biosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · MBX Biosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do MBX Biosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of MBX Biosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in MBX Biosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”